Vimpat (lacosamide) Now Approved by FDA for Primary Generalized Tonic-Clonic Seizures and Expanded Pediatric Use for People Living with Epilepsy
ATLANTA, Nov. 17, 2020 /PRNewswire/ — UCB, a global pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved Vimpat (lacosamide) CV as adjunctive therapy in…
Merck Advances Phase 3 Trial to Evaluate Investigational Islatravir as Once-Monthly Oral PrEP for Women at High Risk for Acquiring HIV-1
KENILWORTH, N.J.–(BUSINESS WIRE) November 16, 2020 — Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced a collaboration with the Bill & Melinda Gates…
Lilly’s Neutralizing Antibody Bamlanivimab (LY-CoV555) Receives Interim Authorization from Health Canada as a Treatment for COVID-19
INDIANAPOLIS, Nov. 20, 2020 /PRNewswire/ — Health Canada today granted authorization under the Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19 for the use of…
New Novartis Analyses for Investigational Inclisiran Demonstrate Consistently Effective and Sustained LDL-C Reduction at Month 17, Regardless of Age and Gender
EAST HANOVER, N.J., Nov. 13, 2020 /PRNewswire/ — Novartis today announced results from two pooled post-hoc analyses of Phase III ORION-9, -10 and -11 trials, evaluating the impact of age and gender on…
NIH Study Aims to Identify Promising COVID-19 Treatments for Larger Clinical Trials
October 13, 2020 — The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved…
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
NEW YORK, Oct. 12, 2020 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced…
Final Results of National Institute of Allergy and Infectious Diseases’ ACTT-1 Trial Published in New England Journal of Medicine Expand Clinical Benefits of Veklury® (remdesivir) for the Treatment of COVID-19
FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 8, 2020– The New England Journal of Medicine (NEJM) today published the final results from the National Institute of Allergy and Infectious Diseases’ (NIAID) double-blind, placebo-controlled, Phase 3 ACTT-1…
Gilead Sciences Update on Supply and Distribution of Veklury (remdesivir) in the United States
FOSTER CITY, Calif.–(BUSINESS WIRE)–Oct. 1, 2020– Since the COVID-19 pandemic began, Gilead has worked diligently to ramp up production and rapidly expand the supply of our investigational antiviral drug Veklury® (remdesivir)…
FDA Approves Anjeso
FDA Approves Anjeso (meloxicam injection) for the Management of Moderate to Severe Pain MALVERN, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) — Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on…
Patient’s place of residence matters when choosing cost-effective anticoagulation therapy
Appropriately selected anticoagulation therapy can help to reduce the medical costs of patients suffering from atrial fibrillation. A new study from the University of Eastern Finland shows that direct oral…